Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,847 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07214532Recruiting
Using a blood test to guide breast cancer therapy
This study tests whether a blood test can help decide when to start additional hormone-blocking therapy for early-stage breast cancer. It aims to see if starting therapy only when the test detects cancer DNA is as effective as giving it to everyone.
Phoenix, ArizonaAges 18 years+ - NCT07213609RecruitingPhase 1/Phase 2
Study of GSK5460025 for advanced solid tumors
This trial tests a new drug, GSK5460025, alone or with other cancer treatments, for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help those whose cancer has a specific genetic feature (dMMR or MSI-H) or who have not responded to standard treatments.
Aurora, ColoradoAges 18 years+ - NCT07214441Enrolling by invitation
BE+ program for lung cancer survivors
This trial tests a program called BE+ for people who have finished treatment for non-small cell lung cancer. It aims to see if the program is practical and helpful for improving health after treatment.
Columbia, South CarolinaAges 21 years+ - NCT05508347RecruitingPhase 2
Testing a new antibody with chemo for locally advanced throat cancer
This study tests nituzumab (a targeted antibody) added to standard induction chemotherapy versus placebo plus chemotherapy. It aims to improve tumor control and safety for people with locally advanced nasopharyngeal (throat) cancer.
Chengdu, SichuanAges 18–70 - NCT06674265RecruitingPhase 1
Natural killer cells for advanced neuroblastoma
This trial tests a new type of immune cell called natural killer (NK) cells from healthy donors to treat neuroblastoma that has not responded to standard treatments. The goal is to see if these cells can help shrink or control the cancer.
TehranAges 2–16 - NCT02781870Recruiting
3D laparoscopic groin hernia repair with special mesh fix
This study looks at a laparoscopic (keyhole) operation to repair a groin (inguinal) hernia using a 3D “visible” mesh, with or without an added fixation method. If you have a first-time hernia on one side and are planning a laparoscopic repair, this trial may be an option to discuss with your surgical team.
GhentAges 18–80 - NCT06923150Recruiting
MiniGo vs. standard care for bowel symptoms after rectal cancer surgery
This trial tests a small, portable device called MiniGo that uses a gentle water rinse to help control bowel symptoms after rectal cancer surgery. It may be an option for people who still have bothersome bowel problems despite trying other treatments.
AmiensAges 18 years+ - NCT04705467Recruiting
3D scanning of needles during gynecologic radiation treatment
This study uses 3D imaging to help guide needle-based radiation treatment for certain gynecologic cancers. If you are already scheduled to receive this type of brachytherapy, the trial may help make the treatment planning more accurate.
London, OntarioAges 18 years+ - NCT04997317RecruitingPhase 1/Phase 2
Lu-177 targeting drug for returning or growing meningioma
This Phase 1/2 study tests a targeted radioactive medicine (Lu-177-satoreotide) for meningiomas that keep coming back or keep growing. It works only if tumor imaging shows the tumor has the right “target” signal, and it aims to see how well it can control the disease and how safe it is.
Basel, Canton of Basel-CityAges 18 years+ - NCT07205718RecruitingPhase 1/Phase 2
Study of TAK-188 for advanced solid tumors
This trial tests a new medicine, TAK-188, for people with certain advanced cancers that have not responded to standard treatments. The goal is to see if it can help shrink or slow the growth of the cancer.
Santa Monica, CaliforniaAges 18 years+ - NCT05738252Recruiting
Frailty tests to assess surgical risk in gynecologic cancers
This trial studies simple “frailty” assessments (tests of strength, memory, and daily functioning) to better predict risk in people with gynecologic cancers who are planning or having surgery. If you qualify, the results may help doctors identify who needs extra support before and after surgery.
Hamilton, OntarioAges 55–110 - NCT07204132Recruiting
Freezing and Immunotherapy for Bladder Cancer
This study tests a combination treatment for people with early-stage bladder cancer who want to avoid bladder removal. It uses a freezing technique (cryoablation) inside the bladder along with immunotherapy drugs to see if this can cure the cancer while keeping the bladder.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT07207824RecruitingPhase 3
Study of a new drug for high-risk bladder cancer
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06930573RecruitingPhase 4
AK112 for high-risk liver cancer after surgery
This study tests a new drug called AK112 (a combination antibody targeting two proteins that help tumors grow) after surgery for liver cancer that has a high chance of returning. The goal is to see if it can prevent the cancer from coming back.
Zhengzhou, HenanAges 18–75 - NCT04849130Recruiting
Compare two surgical MPFL techniques for kneecap dislocation
This trial compares two ways surgeons rebuild a key ligament (the MPFL) to help stop recurrent kneecap dislocations. It may help you by checking which technique works better for stability and recovery.
BaselAges 14 years+ - NCT05209620RecruitingPhase 2
Orelabrutinib plus pemetrexed for lymphoma in the brain
This Phase 2 trial tests a combination medicine (orelabrutinib with pemetrexed) to treat lymphoma that has returned or is not responding, specifically in the brain or spinal fluid. If you qualify, the goal is to shrink measurable tumors and improve control of central nervous system lymphoma.
Zhengzhou, HenanAges 18–75 - NCT07193628RecruitingPhase 1
A new immune cell therapy for recurrent glioblastoma
This trial tests a special immune cell treatment (CAR-T cells) that targets two proteins found on glioblastoma cells. It is for patients whose tumor has come back or not responded to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT07198217RecruitingPhase 2
Chemo, radiation, and immunotherapy for lung cancer
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
Zibo, ShandongAges 18–75 - NCT07194161Recruiting
Study on quality of life after pilonidal cyst recurrence
This study looks at how a return of a pilonidal cyst (an infected bump near the tailbone) affects your quality of life. It is for people who had a first treatment with either surgery or laser and now have a recurrence at least 6 months later.
LyonAges 14 years+ - NCT07193641RecruitingPhase 2
Lattice radiotherapy with standard care for slow-growing lung cancer
This trial tests whether adding a special radiotherapy technique called lattice radiotherapy to your usual cancer treatment can help control NSCLC that has started to grow in a few new spots. If you have up to 5 growing tumors and at least one measures 4.5 cm or larger, this study might be an option.
Hangzhou, ZhejiangAges 18 years+ - NCT07199959Recruiting
Study on why entrectinib stops working in ROS1 lung cancer
This study looks at why the targeted drug entrectinib stops working in some people with ROS1-positive lung cancer. Participants will give blood or tumor samples before and after treatment to help researchers understand resistance.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07184827RecruitingPhase 3
U101 capsules to prevent recurring UTIs in women
This trial tests an oral capsule called U101 to see if it can prevent recurrent urinary tract infections (UTIs) in women who have frequent UTIs. If you've had at least 2 UTIs in the last 6 months or 3 in the last year, you may be able to join.
Chiayi CityAges 20–75 - NCT07187570RecruitingPhase 3
Dapagliflozin to prevent atrial fibrillation recurrence after cardioversion
This trial tests if the diabetes drug dapagliflozin can lower the chance of atrial fibrillation (an irregular heartbeat) coming back after a procedure called electrical cardioversion, which uses a shock to restore a normal heart rhythm. If you have AF and are scheduled for cardioversion, you may be able to join.
LinköpingAges 55 years+ - NCT07187908RecruitingPhase 2
Study of Efbemalenograstim Alfa to prevent low white blood cell counts in cancer patients
This trial tests if a drug called Efbemalenograstim Alfa can help prevent a serious drop in white blood cells (febrile neutropenia) during chemotherapy. It is for patients with solid tumors who have a high or intermediate risk of this condition.
Zhengzhou, HenanAges 18–75
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,847 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.